Multicentre combined chemotherapy protocol for large cell advanced non hodgkin's lymphoma
β Scribed by J. Dumont; P. Charpy-Validire; V. Mosseri; J. Gabarre; C. Belanger; F. Turpin; J. L. Binet; F. Dreyfus; A. Fourquet; M. Janvier; M. LeDoussal; V. Missenard; J. C. Natali; M. Raphael; F. Teillet; F. Teillet-Thiebaud; M. Tulliez; B. Varet; J. R. Vilcoq; B. Asselain
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 702 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0278-0232
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Between October 1985 and October 1989, 75 previously untreated patients with stage III and IV non Hodgkin's lymphoma, large cell type, were treated with an alternating weekly chemotherapy regimen including the following drugs: week 1: Doxorubicin, vincristine, cyclophosphamide, bleomycin, and intrathecal (i.th.) methotrexate and cytarabine; week 2: Methotrexate with leucovorin rescue; week 3: Doxorubicin, ifosfamide with mesna, etoposide, and i.th. methotrexate and cytarabine; week 4: Methotrexate with leucovorin rescue. Complete responders after three cycles according to this schedule (12 weeks) were given 18 gys cranial irradiation and randomized between one additional cycle or three monthly CHOP (consolidation treatment). Among 66 evaluable patients, 53 achieved a complete remission (CR 80 per cent) and seven a partial remission (11 per cent). There were six failures, and nine early deaths during the initial phase, mostly due to septic problems. Fortyβone of the 53 CR patients (77Β±3 per cent) have remained free of disease with a median followβup of 15 months (1β49). Eight of the 12 relapses occurred during the first year, the four others at 13, 14, 16 and 38 months respectively. The 2βyear survival was 63 per cent for the whole group, and 77 per cent for the CR group. No difference has been observed up until now between the two groups with different consolidation treatment. Therefore, this protocol seems to be able to produce a high rate of complete and durable remission. The analysis of prognostic factors suggests that some highβrisk patients should be considered for intensification therapy with the support of autologous bone marrow transplantation.
π SIMILAR VOLUMES
During a 3-year period 39 evaluable patients with stage III and IV non-Hodgkin's lymphomas and unfavorable histologies were treated with a unique chemotherapeutic regimen based on a modified CHOP combination to which was added the nitrosourea, CCNU. Complete response was observed in six of 15 (40%)
Between 1979 and 1985 61 consecutive patients with non-Hodgkin's lymphomas of unfavourable histology (mostly diffuse large cell lymphomas subclassified according to Kiel nomenclature) were treated in our departments by either the CHOP-(n = 34) or the COPBLAM-regimen (n = 27). A retrospective analysi
In a multicentre phase 111 trial 146 previously untreated patients with high grade non-Hodgkin's lymphomas stage I1 IV were randomized to receive either four cycles of CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3-5, predni